Source comparison
AOD-9604 Results After 2 Weeks: Comparison Table
Before evaluating your own two-week experience, it helps to understand what constitutes realistic progress versus marketing exaggeration. The table below compares expected outcomes at the 2-week mark across different peptide protocols. Measurable fat loss (cal
This comparison does not assign a generated winner or score.
- Before evaluating your own two-week experience, it helps to understand what constitutes realistic progress versus marketing exaggeration. The table below compares expected outcomes at the 2-week mark across different peptide protocols.
- Measurable fat loss (calipers, DEXA)
- Minimal to none. Changes within measurement error
- 2–4% body fat reduction in deficit
- 1–3% body weight reduction via appetite suppression
- Fat loss at 2 weeks is biologically implausible with AOD-9604 monotherapy
- Subjective recovery improvements
- Moderate. Reduced DOMS, faster strength return
- Sustained. Consistent faster recovery cycles
- Minimal. Unrelated to peptide mechanism
- Early recovery benefits are the most consistent 2-week marker
- Sleep quality changes
- Mild to moderate. Deeper sleep phases reported
- Consistent improvement in subjective sleep scores
- Variable. GI side effects may disrupt sleep
- Sleep improvements suggest the peptide is bioavailable and active
- Appetite or satiety changes
- None. AOD-9604 does not affect ghrelin or leptin
- None. Mechanism is lipolytic, not appetite-modulating
- Significant. Early and pronounced appetite suppression
- Expecting appetite changes from AOD-9604 reflects mechanism misunderstanding
- Visible subcutaneous fat reduction
- None. Insufficient time for depot shrinkage
- Moderate. Noticeable in abdomen, flanks if in deficit
- Minimal. Weight loss is gradual and systemic
- Visible changes require 6+ weeks even under ideal conditions